Sökning: onr:"swepub:oai:DiVA.org:uu-395591" > Understanding the I...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03465naa a2200373 4500 | |
001 | oai:DiVA.org:uu-395591 | |
003 | SwePub | |
008 | 191021s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3955912 URI |
024 | 7 | a https://doi.org/10.1016/j.xphs.2019.05.0292 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hu, Yang,d 1989-u Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)huaya196 |
245 | 1 0 | a Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling. |
264 | 1 | b Elsevier BV,c 2019 |
338 | a print2 rdacarrier | |
520 | a This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng |
653 | a blood-brain barrier | |
653 | a brain delivery | |
653 | a dose-response relationship | |
653 | a model-based approach | |
653 | a nanocarrier | |
653 | a pharmacokinetics | |
700 | 1 | a Hammarlund-Udenaes, Margaretau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)marghamm |
700 | 1 | a Fridén, Markusu Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Department of Drug Metabolism and Pharmacokinetics, Early Respiratory, Inflammation and Autoimmunity, R&D Biopharmaceuticals, AstraZeneca R&D, Gothenburg, Sweden,tPKPD4 aut0 (Swepub:uu)mafri535 |
710 | 2 | a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org |
773 | 0 | t Journal of Pharmaceutical Sciencesd : Elsevier BVg 108:10, s. 3425-3433q 108:10<3425-3433x 0022-3549x 1520-6017 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-395591 |
856 | 4 8 | u https://doi.org/10.1016/j.xphs.2019.05.029 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy